Advertisement

Melanoma pp 577-589 | Cite as

Immune-Related Adverse Toxicities and Clinical Management

  • Michael Constantin Kirchberger
  • Lucie Heinzerling
Chapter

Abstract

Checkpoint inhibitors are effective in various cancer entities. However, especially in the combination of anti-CTLA-4 antibodies with anti-PD-1 antibodies they induce considerable toxicity with around 56% grade 3/4 adverse events. These side effects may involve skin, the gastrointestinal tract, liver, the endocrine system, and other organ systems. In combination therapy in about a third of patients more than one organ system is affected. Since life-threatening and fatal immune-related adverse events (irAE) have been reported, adequate diagnosis and management is essential. Besides well-known irAE, checkpoint inhibitors can induce a plethora of side effects including neurologic and cardiotoxic events. Prompt diagnosis and management can reduce morbidity and mortality due to these autoimmune side effects.

This chapter gives an overview on how to approach side effects diagnostically and therapeutically in patients under checkpoint inhibitor therapy. It includes information on patient education, important differentials, and algorithms for therapy.

Keywords

Checkpoint inhibitors Autoimmunity Serious adverse events Toxicity Side effect management Ipilimumab Nivolumab Pembrolizumab 

References

  1. 1.
    Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:190–9.  https://doi.org/10.1016/j.ejca.2016.02.025.CrossRefPubMedGoogle Scholar
  2. 2.
    Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013;8:e53745.  https://doi.org/10.1371/journal.pone.0053745.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210–25.  https://doi.org/10.1016/j.ejca.2016.02.024.CrossRefPubMedGoogle Scholar
  4. 4.
    Eggermont AMM, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage III melanoma with Ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845–55.  https://doi.org/10.1056/NEJMoa1611299.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Gaudy-Marqueste C, Monestier S, Franques J, Cantais E, Richard M-A, Grob J-J. A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother. 2013;36:77–8.  https://doi.org/10.1097/CJI.0b013e31827807dd.CrossRefPubMedGoogle Scholar
  6. 6.
    Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.  https://doi.org/10.1056/NEJMoa1003466.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65.  https://doi.org/10.1056/NEJMoa1200694.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.  https://doi.org/10.1056/NEJMoa1200690.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.  https://doi.org/10.1056/NEJMoa1504030.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155–64.  https://doi.org/10.1016/S1470-2045(09)70334-1.CrossRefPubMedGoogle Scholar
  11. 11.
    Bertrand A, Kostine M, Barnetche T, Truchetet M-E, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211.  https://doi.org/10.1186/s12916-015-0455-8.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–33.  https://doi.org/10.1056/NEJMoa1302369.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2014;372:320–30.  https://doi.org/10.1056/NEJMoa1412082.CrossRefPubMedGoogle Scholar
  14. 14.
    Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, et al. Safety and tumor responses with Lambrolizumab (anti–PD-1) in melanoma. N Engl J Med. 2013;369:134–44.  https://doi.org/10.1056/NEJMoa1305133.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372:2521–32.  https://doi.org/10.1056/NEJMoa1503093.CrossRefGoogle Scholar
  16. 16.
    Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu S-M, Sharma P. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer. 2016;4:36.  https://doi.org/10.1186/s40425-016-0139-8.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Dasanu CA, Jen T, Skulski R. Late-onset pericardial tamponade, bilateral pleural effusions and recurrent immune monoarthritis induced by ipilimumab use for metastatic melanoma. J Oncol Pharm Pract. 2017;23(3):231–4.  https://doi.org/10.1177/1078155216635853.CrossRefPubMedGoogle Scholar
  18. 18.
    Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D’Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17:1374–85.  https://doi.org/10.1016/S1470-2045(16)30364-3.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Weber JS, Dummer R, de Pril V, Lebbé C, Hodi FS, MDX010-20 Investigators. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119:1675–82.  https://doi.org/10.1002/cncr.27969.CrossRefPubMedGoogle Scholar
  20. 20.
    Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–30.  https://doi.org/10.1200/JCO.2013.53.0105.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, et al. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer. 2017;75:24–32.  https://doi.org/10.1016/j.ejca.2016.12.038.CrossRefPubMedGoogle Scholar
  22. 22.
    Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016;4:50.  https://doi.org/10.1186/s40425-016-0152-y.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    weber. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): a pooled analysis. ASCO Annual Meeting | Abstracts | Meeting Library; 2015.Google Scholar
  24. 24.
    Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–48.  https://doi.org/10.1016/j.ejca.2015.11.016.CrossRefPubMedGoogle Scholar
  25. 25.
    Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691–7.  https://doi.org/10.1200/JCO.2012.41.6750.CrossRefGoogle Scholar
  26. 26.
    Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother. 2006;29:455–63.  https://doi.org/10.1097/01.cji.0000208259.73167.58.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grünwald V, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016;45:7–18.  https://doi.org/10.1016/j.ctrv.2016.02.003.CrossRefPubMedGoogle Scholar
  28. 28.
    Spain L, Larkin J. Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. Expert Opin Biol Ther. 2016;16:389–96.  https://doi.org/10.1517/14712598.2016.1141195.CrossRefPubMedGoogle Scholar
  29. 29.
    Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol Off J Eur Soc Med Oncol. 2016;27:559–74.  https://doi.org/10.1093/annonc/mdv623.CrossRefGoogle Scholar
  30. 30.
    Lankes K, Hundorfean G, Harrer T, Pommer AJ, Agaimy A, Angelovska I, et al. Anti-TNF-refractory colitis after checkpoint inhibitor therapy: possible role of CMV-mediated immunopathogenesis. Oncoimmunology. 2016;5:e1128611.  https://doi.org/10.1080/2162402X.2015.1128611.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Cheng R, Cooper A, Kench J, Watson G, Bye W, McNeil C, et al. Ipilimumab-induced toxicities and the gastroenterologist. J Gastroenterol Hepatol. 2015;30:657–66.  https://doi.org/10.1111/jgh.12888.CrossRefPubMedGoogle Scholar
  32. 32.
    Horvat TZ, Adel NG, Dang T-O, Momtaz P, Postow MA, Callahan MK, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33:3193–8.  https://doi.org/10.1200/JCO.2015.60.8448.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375–84.  https://doi.org/10.1016/S1470-2045(15)70076-8.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28.  https://doi.org/10.1056/NEJMoa1501824.CrossRefPubMedGoogle Scholar
  35. 35.
    Gupta A, De Felice KM, Loftus EV, Khanna S. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther. 2015;42:406–17.  https://doi.org/10.1111/apt.13281.CrossRefPubMedGoogle Scholar
  36. 36.
    Hundorfean G, Atreya R, Agaimy A, Heinzerling L, Kämpgen E, Schuler G, et al. Fluorescein-guided confocal laser endomicroscopy for the detection of ipilimumab-induced colitis. Endoscopy. 2012;44:E78–9.  https://doi.org/10.1055/s-0031-1291603.CrossRefPubMedGoogle Scholar
  37. 37.
    Uslu U, Agaimy A, Hundorfean G, Harrer T, Schuler G, Heinzerling L. Autoimmune colitis and subsequent CMV-induced hepatitis after treatment with Ipilimumab. J Immunother. 2015;38(5):212.  https://doi.org/10.1097/CJI.0000000000000081.CrossRefPubMedGoogle Scholar
  38. 38.
    Freie Vorträge. JDDG J Der Dtsch Dermatologischen Gesellschaft. 2015;13:1–19.  https://doi.org/10.1111/ddg.12783.
  39. 39.
    Gaudy C, Clévy C, Monestier S, Dubois N, Préau Y, Mallet S, et al. Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes. Diabetes Care. 2015;38:e182–3.  https://doi.org/10.2337/dc15-1331.CrossRefPubMedGoogle Scholar
  40. 40.
    Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016;60:12–25.  https://doi.org/10.1016/j.ejca.2016.02.010.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 2016;28:254–63.  https://doi.org/10.1097/CCO.0000000000000290.CrossRefPubMedGoogle Scholar
  42. 42.
    Carlos G, Anforth R, Chou S, Clements A, Fernandez-Peñas P. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res. 2015;25:265–8.  https://doi.org/10.1097/CMR.0000000000000155.CrossRefPubMedGoogle Scholar
  43. 43.
    Naidoo J, Schindler K, Querfeld C, Busam K, Cunningham J, Page DB, et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res. 2016;4:383–9.  https://doi.org/10.1158/2326-6066.CIR-15-0123.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Jour G, Glitza IC, Ellis RM, Torres-Cabala CA, Tetzlaff MT, Li JY, et al. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol. 2016;43:688–96.  https://doi.org/10.1111/cup.12717.CrossRefPubMedGoogle Scholar
  45. 45.
    Goldinger SM, Stieger P, Meier B, Micaletto S, Contassot E, French LE, et al. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res. 2016;22:4023–9.  https://doi.org/10.1158/1078-0432.CCR-15-2872.CrossRefPubMedGoogle Scholar
  46. 46.
    Hwang SJE, Carlos G, Wakade D, Byth K, Kong BY, Chou S, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol. 2016;74:455–61.  https://doi.org/10.1016/j.jaad.2015.10.029.CrossRefPubMedGoogle Scholar
  47. 47.
    Mutgi KAJ, Milhem M, Swick BL, Liu V. Pityriasis lichenoides chronica–like drug eruption developing during pembrolizumab treatment for metastatic melanoma. JAAD Case Reports. 2016;2:343–5.  https://doi.org/10.1016/j.jdcr.2016.06.012.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Uemura M, Faisal F, Haymaker C, McQuail N, Sirmans E, Hudgens CW, et al. A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. J Immunother Cancer. 2016;4:55.  https://doi.org/10.1186/s40425-016-0157-6.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2016:1–8.  https://doi.org/10.1136/annrheumdis-2016-209595.
  50. 50.
    Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014;21:371–81.  https://doi.org/10.1530/ERC-13-0499.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375–91.  https://doi.org/10.1093/annonc/mdv383.CrossRefPubMedGoogle Scholar
  52. 52.
    de Filette J, Jansen Y, Schreuer M, Everaert H, Velkeniers B, Neyns B, et al. Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J Clin Endocrinol Metab. 2016;101(11):4431–9.  https://doi.org/10.1210/jc.2016-2300.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Orlov S, Salari F, Kashat L, Walfish PG. Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. J Clin Endocrinol Metab. 2015;100:1738–41.  https://doi.org/10.1210/jc.2014-4560.CrossRefPubMedGoogle Scholar
  54. 54.
    Verma I, Modi A, Tripathi H, Agrawal A. Nivolumab causing painless thyroiditis in a patient with adenocarcinoma of the lung. BMJ Case Rep. 2016:bcr2015213692.  https://doi.org/10.1136/bcr-2015-213692.
  55. 55.
    Okano Y, Satoh T, Horiguchi K, Toyoda M, Osaki A, Matsumoto S, et al. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma. Endocr J. 2016;63:905–12.  https://doi.org/10.1507/endocrj.EJ16-0161.CrossRefPubMedGoogle Scholar
  56. 56.
    Ishikawa M, Oashi K. Case of hypophysitis caused by nivolumab. J Dermatol. 2016;44(1):109–10.  https://doi.org/10.1111/1346-8138.13437.CrossRefPubMedGoogle Scholar
  57. 57.
    Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257–65.  https://doi.org/10.1016/S1470-2045(15)70054-9.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    O’Kane GM, Lyons TG, Colleran GC, Ahmad MW, Alken S, Kavanagh EC, et al. Late-onset paraplegia after complete response to two cycles of Ipilimumab for metastatic melanoma. Oncol Res Treat. 2014;37:757–60.  https://doi.org/10.1159/000368316.CrossRefPubMedGoogle Scholar
  59. 59.
    Tarhini A. Immune-mediated adverse events associated with Ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo). 2013;2013:1–19.  https://doi.org/10.1155/2013/857519.CrossRefGoogle Scholar
  60. 60.
    Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30:825–30.  https://doi.org/10.1097/CJI.0b013e318156e47e.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncology. 2014;16:589–93.  https://doi.org/10.1093/neuonc/nou001.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Thaipisuttikul I, Chapman P, Avila EK. Peripheral neuropathy associated with Ipilimumab: a report of 2 cases. J Immunother. 2015;38:77–9.  https://doi.org/10.1097/CJI.0000000000000070.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Johnson DB, Saranga-Perry V, Lavin PJM, Bryan Burnette W, Clark SW, Uskavitch DR, et al. Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol. 2015;33:e122–4.  https://doi.org/10.1200/JCO.2013.51.1683.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Abdallah A-O, Herlopian A, Ravilla R, Bansal M, Chandra-Reddy S, Mahmoud F, et al. Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: a case report and review of literature. J Oncol Pharm Pract. 2016;22:537–42.  https://doi.org/10.1177/1078155215572932.CrossRefPubMedGoogle Scholar
  65. 65.
    Murphy KP, Kennedy MP, Barry JE, O’Regan KN, Power DG. New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment. Oncol Res Treat. 2014;37:351–3.  https://doi.org/10.1159/000362614.CrossRefPubMedGoogle Scholar
  66. 66.
    Maurice C, Schneider R, Kiehl T-R, Bavi P, Roehrl MHA, Mason WP, et al. Subacute CNS demyelination after treatment with nivolumab for melanoma. Cancer Immunol Res. 2015;3:1299–302.  https://doi.org/10.1158/2326-6066.CIR-15-0141.CrossRefPubMedGoogle Scholar
  67. 67.
    Mandel JJ, Olar A, Aldape KD, Tremont-Lukats IW. Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci. 2014;344:229–31.  https://doi.org/10.1016/j.jns.2014.06.023.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Vogel WV, Guislain A, Kvistborg P, Schumacher TNM, Haanen JBAG, Blank CU. Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol. 2012;30:e7–10.  https://doi.org/10.1200/JCO.2011.37.9693.CrossRefPubMedGoogle Scholar
  69. 69.
    Eckert A, Schoeffler A, Dalle S, Phan A, Kiakouama L, Thomas L. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology. 2009;218:69–70.  https://doi.org/10.1159/000161122.CrossRefPubMedGoogle Scholar
  70. 70.
    Wilgenhof S, Morlion V, Seghers AC, Du Four S, Vanderlinden E, Hanon S, et al. Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor. Anticancer Res. 2012;32:1355–9.PubMedGoogle Scholar
  71. 71.
    Barjaktarevic IZ, Qadir N, Suri A, Santamauro JT, Stover D. Organizing pneumonia as a side effect of Ipilimumab treatment of melanoma. Chest. 2013;143:858–61.  https://doi.org/10.1378/chest.12-1467.CrossRefPubMedGoogle Scholar
  72. 72.
    Berthod G, Lazor R, Letovanec I, Romano E, Noirez L, Stalder JM, et al. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol. 2012;30:e156–9.  https://doi.org/10.1200/JCO.2011.39.3298.CrossRefPubMedGoogle Scholar
  73. 73.
    Nishino M, Chambers ES, Chong CR, Ramaiya NH, Gray SW, Marcoux JP, et al. Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer. Cancer Immunol Res. 2016;4:289–93.  https://doi.org/10.1158/2326-6066.CIR-15-0267.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Steenbruggen TG, van den Heuvel MM, Blank CU, van Dieren JM, Haanen JBAG, Kok M. No hair loss, but colitis or pneumonitis: unique side effects of immune checkpoint inhibitors for cancer. Ned Tijdschr Geneeskd. 2016;160:A9873.PubMedGoogle Scholar
  75. 75.
    Sano T, Uhara H, Mikoshiba Y, Kobayashi A, Uchiyama R, Tateishi K, et al. Nivolumab-induced organizing pneumonia in a melanoma patient. Jpn J Clin Oncol. 2016;46:270–2.  https://doi.org/10.1093/jjco/hyv199.CrossRefPubMedGoogle Scholar
  76. 76.
    Nishino M, Sholl LM, Hatabu H, Ramaiya NH, Hodi FS. Anti–PD-1–related pneumonitis during cancer immunotherapy. N Engl J Med. 2015;373:288–90.  https://doi.org/10.1056/NEJMc1505197.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Voskens C, Cavallaro A, Erdmann M, Dippel O, Kaempgen E, Schuler G, et al. Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss. J Clin Oncol. 2012;30:e356–7.  https://doi.org/10.1200/JCO.2011.41.4359.CrossRefPubMedGoogle Scholar
  78. 78.
    Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody–induced lupus nephritis. N Engl J Med. 2009;361(2):211.  https://doi.org/10.1056/NEJMc0904283.CrossRefPubMedGoogle Scholar
  79. 79.
    Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749–55.  https://doi.org/10.1056/NEJMoa1609214.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018. https://doi.org/10.1016/j.jacc.2018.02.037.
  81. 81.
    Tajmir-Riahi A, Bergmann T, Schmid M, Agaimy A, Schuler G, Heinzerling L. Life-threatening Autoimmune Cardiomyopathy Reproducibly Induced in a Patient by Checkpoint Inhibitor Therapy. J Immunother. 2018;41(1):35–8. https://doi.org/10.1097/CJI.0000000000000190.CrossRefPubMedGoogle Scholar
  82. 82.
    Delyon J, Mateus C, Lambert T. Hemophilia a induced by ipilimumab. N Engl J Med. 2011;365:1747–8.  https://doi.org/10.1056/NEJMc1110923.CrossRefPubMedGoogle Scholar
  83. 83.
    Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen Y-B, et al. Disabling immune tolerance by programmed Death-1 blockade with Pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol. 2013;31:4199–206.  https://doi.org/10.1200/JCO.2012.48.3685.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    du Rusquec P, Saint-Jean M, Brocard A, Peuvrel L, Khammari A, Quéreux G, et al. Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma. J Immunother. 2014;37:348–50.  https://doi.org/10.1097/CJI.0000000000000041.CrossRefPubMedGoogle Scholar
  85. 85.
    Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and Unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016;22:886–94.  https://doi.org/10.1158/1078-0432.CCR-15-1136.CrossRefPubMedGoogle Scholar
  86. 86.
    Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152:45.  https://doi.org/10.1001/jamadermatol.2015.2707.CrossRefPubMedGoogle Scholar
  87. 87.
    Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350:1079–84.  https://doi.org/10.1126/science.aad1329.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Michael Constantin Kirchberger
    • 1
  • Lucie Heinzerling
    • 1
  1. 1.Department of DermatologyUniversity Hospital ErlangenErlangenGermany

Personalised recommendations